Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Belgium /
      2. Our innovation /
      3. Focus areas /
      4. PAH

      Pulmonary hypertension
      (PAH)

      We understand the ways in which pulmonary hypertension (PAH) can impair daily life, and are committed to helping to improve comprehension and time to diagnoses of this group of conditions within the medical profession. We are here to help those affected by PAH to lead a full life and receive optimal treatment at the right time.
      11_2024_UnderstandingPAH.webp
      Understanding pulmonary hypertension
      PAH is a serious and progressive disease with various causes and no cure. [1], [2]

      There are five groups of PAH, as defined by the World Health Organization (WHO). All are severe diseases characterised by high blood pressure in the lungs.[1]

      Our focus has been on a specific, rare form of PAH (WHO Group 1) called pulmonary arterial hypertension (PAH).[1]
      11_2024_goal.webp
      Our goal is to give people with PAH a full life
      We are spearheading a new era for PAH, working to transform the disease into a long-term manageable condition, so that patients can live a full life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.
      We want to use our full range of resources to tackle PAH. From investment in research and development of new therapies to innovation in medical devices and screening solutions, our commitment to improving outcomes end-to-end along patient pathways is real. We're focused not only on how we treat PAH but on a broader spectrum of goals for the PAH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.
      11_2024_focus on PAH.webp
      Our focus on PAH
      PAH (WHO Group 1) is a rare, progressive and relentless disease, where the pressure in the blood vessels of the lungs is elevated, resulting in stress on the heart. [1]

      Despite recent advances, PAH remains a severely debilitating condition that leads to heart disease and early death. Early diagnosis and treatment are critical to helping improve life expectancy but PAH is difficult to diagnose and there is currently no cure.[2]
      We’re working to transform PAH into a long-term, manageable condition so patients can lead a full life. Johnson & Johnson's aim is to increase the mainstream awareness around PAH so that no patient goes undiagnosed and there’s no delay in diagnosis.
      I would describe PAH as like being in a car which won’t go over 10KPH”
      Patient with PAH
      References

      [1] Humbert M, , et al 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43(38):3618–3731.
      [2] Pulmonary Hypertension Association. About PH. Available at https://phassociation.org/patients/aboutph/. accessed October 2022.

      ©Janssen-Cilag NV/B.V., a Johnson&Johnson company - CP-490861 - Approval date: 11-2024, vu(er Luc Van Oevelen, Antwerseweg 15-17, 2340 Beerse